Cell biology of CML cells

Leukemia

Volumn 13, Issue , 1999, Pages 65-71

  Gordon, M Y ^a   Dazzi, F ^a   Marley, S B ^a   Lewis, J L ^a   Nguyen, D ^a   Grand, F H ^a   Davidson, R J ^a   Goldman, J M ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

CML; Kinetics; Progenitor cells

Indexed keywords

APOPTOSIS; CELL DIFFERENTIATION; CELL GROWTH; CELL KINETICS; CELL LOSS; CELL MATURATION; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONFERENCE PAPER; CYTOLOGY; HEMATOPOIESIS; LEUKEMIA CELL; ONCOGENE; PRIORITY JOURNAL; STEM CELL;

EID: 0032965810     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2401281     Document Type: Review

References (45)

1. Gordon MY, Goldman JM. Cellular and molecular mechanisms in chronic myeloid leukaemia: biology and treatment. Br J Haematol 1996; 95: 10-20.
2. + cells circulating in the blood of chronic phase chronic myeloid leukemia patients. Leukemia 1997; 11: 1486-1492.
3. Verfaillie CM, Miller WJ, Boylam K, McGlave PB. Selection of benign primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of DR antigen expression. Blood 1992; 79: 1003-1010.
4. Kamada N, Uchino H. Chronological sequence in appearance of clinical and laboratory findings characteristic of chronic myelocytic leukemia. Blood 1978; 51: 843-850.
5. Daley GQ, Baltimore D. Transformation of an interleukin-3 dependent hematopoietic cell line by the chronic myelogenous leukemia-specific bcr-abl protein. Proc Natl Acad Sci USA 1988; 85: 9312-9315.
6. Hariharan IK, Adams JM, Cory S. Bcr-abl oncogene renders myeloid cell line factor independent: potential autocrine mechanisms in chronic myeloid leukemia. Oncogene Res 1988; 3: 387-399.
7. Santucci MA, Anklesaria P, Laneuville P, Das IJ, Fitzgerald TJ, Greenberger JS. Expression of p210 BCR/ABL increases hematopoietic progenitor cell radiosensitivity. Int J Radiat Oncol Biol Phys 1993; 26: 881-889.
8. Amos TAS, Lewis JL, Grand FH, Gooding RP, Goldman JM, Gordon MY. Apoptosis in chronic myeloid leukaemia: normal responses by progenitor cells to growth factor deprivation, Xirradiation and glucocorticoids. Br J Haematol 1995; 91: 387-393.
9. Bedi A, Zehnbauer RA, Barber JP, Sharkis SJ, Jones RJ. Inhibition of apoptosis by BCR-ABL in chronic myelogenous leukemia. Blood 1994; 83: 2038-2044.
10. Albrecht T, Schwab R, Henkes M, Peschel C, Huber C, Aulitzky WE. Primary proliferating immature myeloid cells from CML patients are not resistant to induction of apoptosis by DNA damage and growth factor withdrawal. Br J Haematol 1996; 95: 501-507.
11. Roger R, Isaad C, Pallardy M, Leglise M-C, Turhan AG, Bertoglio J, Breard J. BCR-ABL does not prevent apoptotic death induced by human natural killer or lymphokine activated killer cells. Blood 1996; 87: 1113-1122.
12. Thiele J, Zirbes TK, Lorenzen J, Kvasnicka HM, Dresbach S, Manich B, Leder LD, Niederle N, Diehl V, Fischer R. Apoptosis and proliferation (PCNA labelling) in CML: a comparative immunohistological study of bone marrow biopsies following interferon and busulphan therapy. J Pathol 1997; 181: 316-322.
13. Athens JW, Raab SO, Haab OP, Boggs DR, Aschenbrucker H, Cartwright GE, Wintrobe MM. Leukokinetic studies X. Blood granulocyte kinetics in chronic myelocytic leukemia. J Clin Invest 1965; 44: 765-777.
14. Galbraith PR. Studies on the longevity, sequestration and release of the leukocytes in chronic myelogenous leukemia. J Assoc Med Canad 1966; 95: 511-521.
15. Galbraith PR, Abu-Zahra HT. Granulopoiesis in chronic granulocytic leukaemia. Br J Haematol 1972; 22: 135-143.
16. Gisslinger H, Kurzrock R, Wetzler M, Tucker S, Kantarjian H, Robertson B, Talpaz M. Apoptosis in chronic myelogenous leukemia: studies of stage-specific differences. Leuk Lymphoma 1997; 25: 121-133.
17. Stryckmans PA, Debusscher L, Collard E. Cell kinetics in chronic granulocytic leukaemia (CGL). Clin Haematol 1977; 6: 21-40.
18. Pedersen B. Kinetics and cell function. In: MT Shaw (ed). Chronic Granulocytic Leukaemia. Praeger Scientific Publishers: Eastbourne, New York, 1982, pp 93-135.
19. Vincent PC. Cell kinetics of the leukemias. In: F Gunz, AG Baikie (eds). Leukemia 3rd edn. Grune and Stratton: New York, 1974, pp 189-221.
20. Clarkson BD, Strife A, Wisniewski D, Lambek C, Carpino N. New understanding of the pathogenesis of CML: a prototype of early neoplasia. Leukemia 1997; 11: 1404-1428.
21. Selleri C, Sato T, Del-Vecchio L, Luciano L, Barrett AJ, Young NS, Maciejewski JP. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon alpha in chronic myelogenous leukemia. Blood 1997; 89: 957-964.
22. Carlo-Stella C, Dotti G, Mangoni L, Regazzi E, Garau D, Bonati A, Almici C, Sammarelli G, Salvodo B, Rizzo MT, Rizzoli V. Selection of myeloid progenitors lacking BCR/ABL mRNA in chronic myelogenous leukemia patients after in vitro treatment with the tyrosine kinase inhibitor genistein. Blood 1996; 88: 3091-3100.
23. Eaves CJ, Eaves AC. Stem cell kinetics. Bailliere’s Clin Haematol 1997; 10: 233-257.
24. Gordon MY, Dowding CR, Riley GP, Goldman JM, Greaves MF. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature 1987; 328: 342-344.
25. Upadhyaha G, Guba S, Sih S, Feinberg A, Talpaz M, Kantajian H, Deisseroth A, Emerson S. Interferon-alpha restores the deficient expression of the cyto-adhesion molecule lymphocyte function antigen-3 by chronic myelogenous leukemia progenitor cells. J Clin Invest 1991; 88: 2131-2136.
26. Verfaillie CM, McCarthy JB, McGlave PB. Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Blood 1992; 90: 1232-1241.
27. Ghaffari S, Dougherty GJ, Eaves AC, Eaves CJ. Diverse effects of anti-CD44 antibodoes on the stromal cell-mediated support of S71 normal but not leukemic (CML) hematopoiesis in vitro. Br J Haematol 1997; 97: 22-28.
28. Gordon MY, Lewis JL, Marley SB, Grand FH, Goldman JM. Stromal cells negatively regulate primitive haemopoietic progenitor cell activation via a phosphatidylinositol-anchored cell adhesion/signalling mechanism. Br J Haematol 1997; 96: 647-653.
29. Gordon MY. Plastic-adherent cells in human bone marrow generate long-term hematopoiesis in vitro. Leukemia 1994; 8: 865-870.
30. Gordon MY, Lewis JL, Grand FH, Marley SB, Goldman JM. Phenotype and progeny of primitive adherent human hematopoietic progenitors. Leukemia 1996; 10: 1347-1353.
31. Dowding CR, Gordon MY, Goldman JM. Primitive progenitor cells in the blood of patients with chronic granulocytic leukemia. Int J Cell Cloning 1986; 4: 331-340.
32. Udomsakdi C, Eaves CJ, Swolin B, Reid DS, Barnett MJ, Eaves AC. Rapid decline of chronic myeloid leukemia cells in long-term culture due to a defect at the stem cell level. Proc Natl Acad Sci USA 1992; 89: 6192-6196.
33. Skipper HE, Perry S. Kinetics of normal and leukemic leukocyte populations and relevance to chemotherapy. Cancer Res 1970; 30: 1883-1897.
34. Marley SB, Lewis JL, Scott MA, Goldman JM, Gordon MY. Evaluation of ‘discordant maturation’ in chronic myeloid leukaemia using cultures of primitive progenitor cells and their production of clonogenic progeny (CFU-GM). Br J Haematol 1996; 95: 299-305.
35. Strife A, Clarkson B. Biology of chronic myelogenous leukemia: is discordant maturation the primary defect? Semin Hematol 1988; 25: 1-19.
36. Eaves CJ, Eaves AC. Cell culture studies in CML. Baillière’s Clin Haematol 1987; 1: 931-961.
37. Gordon MY, Marley SB, Lewis JL, Davidson RJ, Grand FH, Reiter A, Goldman JM. Interferon-alfa (IFN-alfa) preferentially inhibits the capacity for self-renewal of CFU-GM from patients with CML and spares normal CFU-GM. Blood 1997; 90: 250 (Abstr.).
38. Chervenick PA, Ellis LD, Pan SF, Lawson AL. Human leukemia cells: in vitro growth of colonies containing the Philadelphia chromosome. Science 1971; 174: 1134-1136.
39. Olofsson T, Olsson I. Granulopoiesis in chronic myeloid leukemia II serial cloning of blood and bone marrow cells in agar culture. Blood 1976; 48: 351-360.
40. Clift RA, Anasetti C. Allografting for chronic myeloid leukaemia. Baillière’s Clin Haematol 1997; 10: 319-336.
41. Goldman JM. Management of chronic myeloid leukaemia. Blood Rev 1994; 8: 21-29.
42. Talpaz M, Kantarjian HM, O’Brien S, Kurzrock R. The MD Anderson Cancer Center experience with interferon-a therapy in chronic myelogenous leukaemia. Baillière’s Clin Haematol 1997; 10: 291-305.
43. Richards SM. Interferon-a: results from randomized trials. Baillière’s Clin Haematol 1997; 10: 307-318.
44. Dowding C, Guo A-P, Osterholz J, Siczkowski M, Goldman J, Gordon M. Interferon-a overrides the deficient adhesion of chronic myeloid leukemia primitive progenitor cells to bone marrow stromal cells. Blood 1991; 78: 499-505.
45. Bhatia R, McCarthy JB, Verfaillie CM. Interferon-a restores normal negative regulation of CML progenitor proliferation by the marrow microenvironment by restoring normal b1 integrin mediated proliferation inhibition. Blood 1996; 87: 3883-3891.